Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Epidermal Growth Factor Receptor 2 (HER2)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT07615751
What this trial is testing

Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 502
Not applicableStudy completedNCT03841266
What this trial is testing

Recurrence Risk Evaluation by 21-gene Detection

Who this might be right for
Relationship and Consistency Analysis
Xijing Hospital 220
Testing effectiveness (Phase 2)Looking for participantsNCT05749900
What this trial is testing

First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)

Who this might be right for
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
Yonsei University 44
Not applicableNot Yet RecruitingNCT07098507
What this trial is testing

De-escalation in Axillary Surgery for Early-stage Breast Cancer

Who this might be right for
Omitting Sentinel Lymph Node Biopsy in Early-stage Breast Cancer
Clinical Hospital Center Rijeka 620
Not applicableUnknownNCT05750693
What this trial is testing

PIK3CA in HER2+ BC and pCR Trial

Who this might be right for
HER2-positive Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 58
Early research (Phase 1)Study completedNCT05732428
What this trial is testing

Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China

Who this might be right for
Breast Cancer
Pfizer 9
Large-scale testing (Phase 3)UnknownNCT02344472
What this trial is testing

Detect V / CHEVENDO (Chemo vs. Endo)

Who this might be right for
Metastatic Breast Cancer
Prof. Wolfgang Janni 271
Not applicableUnknownNCT05491057
What this trial is testing

Treatment Patterns of Neratinib in HER2+ EBC in China

Who this might be right for
Breast Cancer
Pierre Fabre Medicament 500
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06250777
What this trial is testing

Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases

Who this might be right for
Non Small Cell Lung Cancer
Yonsei University 27
Large-scale testing (Phase 3)Study completedNCT00004067
What this trial is testing

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

Who this might be right for
Breast Cancer
NSABP Foundation Inc 2,130
Testing effectiveness (Phase 2)Study completedNCT02488564
What this trial is testing

Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer

Who this might be right for
HER-2 Positive Breast Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 49
Testing effectiveness (Phase 2)UnknownNCT05318339
What this trial is testing

Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Carcinoma, Transitional CellHER-2 Gene Amplification
Chinese Academy of Medical Sciences 30
Testing effectiveness (Phase 2)Looking for participantsNCT06092892
What this trial is testing

IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases

Who this might be right for
Breast CancerAxillary Nodal DiseaseFemale Breast Cancer+3 more
Alice Chung 45
Testing effectiveness (Phase 2)UnknownNCT05296577
What this trial is testing

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Henan Cancer Hospital 134
Not applicableLooking for participantsNCT06905301
What this trial is testing

Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 240
Not applicableUnknownNCT05167643
What this trial is testing

H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study

Who this might be right for
Advanced HR+ HER2 Negative Breast Carcinoma
Tianjin Medical University Cancer Institute and Hospital 40
Not applicableUnknownNCT02656589
What this trial is testing

MicroRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin

Who this might be right for
Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117
What this trial is testing

Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 329
Large-scale testing (Phase 3)Active Not RecruitingNCT02445391
What this trial is testing

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeInvasive Breast Carcinoma+9 more
ECOG-ACRIN Cancer Research Group 415
Testing effectiveness (Phase 2)UnknownNCT05996952
What this trial is testing

RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer
West China Hospital 77
Next Page